回生口服液用于非小细胞肺癌围手术期抗凝治疗专家共识(2016版)
原发性肺癌是我国发病率和死亡率增长最快,对人群健康和生命威胁最大的恶性肿瘤,也是导致我国人群癌症相关死亡的首要原因([1,2])。非小细胞肺癌占全部肺癌患者的85%左右。迄今为止,手术治疗仍是早期非小细胞肺癌的最佳治疗方法([1])。...
Saved in:
Published in | 中国肺癌杂志 Vol. 19; no. 11; pp. 721 - 724 |
---|---|
Main Author | |
Format | Journal Article |
Language | Chinese |
Published |
2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 原发性肺癌是我国发病率和死亡率增长最快,对人群健康和生命威胁最大的恶性肿瘤,也是导致我国人群癌症相关死亡的首要原因([1,2])。非小细胞肺癌占全部肺癌患者的85%左右。迄今为止,手术治疗仍是早期非小细胞肺癌的最佳治疗方法([1])。 |
---|---|
Bibliography: | Qjnghua ZHOUl, Junfeng LIU2, Xiaoguang YANG3, Helin ZHANG4, Fanyi KONGs, Guochen WANG6, Xianli MENG2, Zhiquan CHEN6, Lijun LIU7, Lu LI, Xiongzhi Wi, Yang GUO(1.Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; 2Forth Hospital of Hebei Medical Univer- sity/Tumor Hospital of Hebei Province, Shifiazhuang 030011, China; 3Handan Central Hospital, Handan 036001, China; *The Sec- ond Hospital of Hebei Medical University, Shijiazhuang 030000, China; s Cangzhou Central Hospital, Cangzhou 061001, China; 6North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China; 7Hebei General Hospital, Shiiiazhuang 03003.5, China; a Cancer Hospital/Institute, Tianiin Medical University, Tianjin 300040, China) 12-1395/R |
ISSN: | 1009-3419 1999-6187 |